skip to Main Content

Principal Investigator

Adam S. Sperling, MD, PhD

Dr. Sperling received his medical degree and PhD in Biological Chemistry from the University of California, Los Angeles in 2011, where he worked on mechanisms of epigenetic gene regulation in the lab of Dr. Michael Grunstein. He completed his residency in internal medicine at the Brigham and Women’s Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He is board certified in Internal Medicine, Medical Oncology, and Hematology. He completed his post-doctoral fellowship in the laboratory of Dr. Benjamin Ebert. His research focuses on understanding the mechanisms of disease evolution from pre-malignant conditions and the development of drug resistance in multiple myeloma and other hematologic malignancies. In the clinic he cares for patients with multiple myeloma, monoclonal gammopathies and clonal hematopoiesis.

Postdoctoral Researchers

Ravi K. Dutta, PhD

Dr. Dutta received his PhD from the Department of Biomedical and Clinical Sciences, Linköping University, Sweden. He joined the Sperling Lab in November of 2021. His research focuses on understanding the mechanism of thalidomide analog resistance in multiple myeloma.

Julian Partha Bhowmik, MD

Julian Partha Bhowmik is a physician from Germany who recently received his medical degree from the Eberhard Karls University Tuebingen, Germany. He did his experimental doctoral thesis in basic cardiovascular research at the Department of Cardiology and Angiology, at University Hospital of Tuebingen.

He joined the Sperling Lab in September 2022. Here, his research focuses on the epxression and mechanism of the regulation of key cell surface markers in hematological malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Technical Research Associates

Vanessa A Quevedo Barrios, BA

Vanessa graduated from Williams College in 2021 where she majored in Chemistry and Arabic. In the Sperling Lab, her work focuses on understanding hematological malignancies.

Back To Top